Disease characteristics and overall survival in Burkitt lymphoma/leukemia patients (N = 363)
| . | . | OS . | |
|---|---|---|---|
| Disease characteristics . | Frequency (%) . | Total, % . | P . |
| ECOG performance status | |||
| 0-2 | 285 (93) | 82 ± 2 | |
| 3-4 | 20 (7) | 74 ± 10 | .25 |
| Gender | |||
| Male | 253 (70) | 84 ± 2 | |
| Female | 110 (30) | 70 ± 5 | .004 |
| Age* | |||
| 15-25 y | 69 (19) | 90 ± 4 | |
| 26-55 y | 196 (54) | 84 ± 3 | <.0001 |
| >55 y | 98 (27) | 62 ± 5 | |
| Karyotype | |||
| t(8;14), t(2;8), t(8;22), c-myc | 125 (80) | 77 ± 4 | .92 |
| No typical aberrations | 32 (20) | 78 ± 8 | |
| White blood cells | |||
| <30 000/µL | 317 (94) | 83 ± 2 | .007 |
| >30 000/µL | 21 (6) | 62 ± 11 | |
| Platelets | |||
| <25 000/µL | 38 (11) | 53 ± 8 | <.0001 |
| >25 000/µL | 302 (89) | 85 ± 2 | |
| Hemoglobin | |||
| <8 g/dL | 10 (3) | 70 ± 14 | .31 |
| >8 g/dL | 329 (97) | 81 ± 2 | |
| LDH | |||
| Within reference range (≤250 U/L) | 90 (26) | 95 ± 3 | |
| Moderately increased (>250-500 U/L) | 67 (20) | 76 ± 6 | .0006 |
| Increased (>500 U/L) | 184 (54) | 75 ± 3 | |
| Involved localizations | |||
| Lymph node | |||
| Yes | 261 (77) | 83 ± 2 | .20 |
| No | 79 (23) | 76 ± 5 | |
| Extranodal involvement | |||
| Yes | 297 (86) | 79 ± 3 | .08 |
| No | 49 (14) | 91 ± 4 | |
| CNS | |||
| Yes | 35 (10) | 67 ± 8 | .02 |
| No | 306 (90) | 82 ± 2 | |
| Bone marrow | |||
| Yes | 143 (42) | 67 ± 4 | <.0001 |
| No | 201 (58) | 90 ± 2 | |
| Other localizations | |||
| Mediastinal tumor | 26 (8) | ||
| Pleura | 55 (16) | ||
| Pericardium | 11 (3) | ||
| Spleen | 43 (13) | ||
| Liver | 49 (14) | ||
| Tonsils | 16 (5) | ||
| Thyroid | 7 (2) | ||
| Uterus/adnexa | 13 (4) | ||
| Testes/ovaries | 23 (7) | ||
| Kidney | 16 (5) | ||
| Lung | 8 (2) | ||
| Stomach | 31 (9) | ||
| Gut | 85 (25) | ||
| Bone | 28 (8) | ||
| Other | 76 (23) | ||
| Stage | |||
| I-II | 100 (29) | 90 ± 3 | .002 |
| III-IV | 249 (71) | 76 ± 3 | |
| IPI | |||
| low (0-2) | 140 (49) | 90 ± 3 | .0005 |
| high (3-5) | 146 (51) | 75 ± 4 | |
| aaIPI | |||
| low (0-1) | 111 (37) | 93 ± 3 | <.0001 |
| high (2-3) | 192 (63) | 74 ± 3 | |
| . | . | OS . | |
|---|---|---|---|
| Disease characteristics . | Frequency (%) . | Total, % . | P . |
| ECOG performance status | |||
| 0-2 | 285 (93) | 82 ± 2 | |
| 3-4 | 20 (7) | 74 ± 10 | .25 |
| Gender | |||
| Male | 253 (70) | 84 ± 2 | |
| Female | 110 (30) | 70 ± 5 | .004 |
| Age* | |||
| 15-25 y | 69 (19) | 90 ± 4 | |
| 26-55 y | 196 (54) | 84 ± 3 | <.0001 |
| >55 y | 98 (27) | 62 ± 5 | |
| Karyotype | |||
| t(8;14), t(2;8), t(8;22), c-myc | 125 (80) | 77 ± 4 | .92 |
| No typical aberrations | 32 (20) | 78 ± 8 | |
| White blood cells | |||
| <30 000/µL | 317 (94) | 83 ± 2 | .007 |
| >30 000/µL | 21 (6) | 62 ± 11 | |
| Platelets | |||
| <25 000/µL | 38 (11) | 53 ± 8 | <.0001 |
| >25 000/µL | 302 (89) | 85 ± 2 | |
| Hemoglobin | |||
| <8 g/dL | 10 (3) | 70 ± 14 | .31 |
| >8 g/dL | 329 (97) | 81 ± 2 | |
| LDH | |||
| Within reference range (≤250 U/L) | 90 (26) | 95 ± 3 | |
| Moderately increased (>250-500 U/L) | 67 (20) | 76 ± 6 | .0006 |
| Increased (>500 U/L) | 184 (54) | 75 ± 3 | |
| Involved localizations | |||
| Lymph node | |||
| Yes | 261 (77) | 83 ± 2 | .20 |
| No | 79 (23) | 76 ± 5 | |
| Extranodal involvement | |||
| Yes | 297 (86) | 79 ± 3 | .08 |
| No | 49 (14) | 91 ± 4 | |
| CNS | |||
| Yes | 35 (10) | 67 ± 8 | .02 |
| No | 306 (90) | 82 ± 2 | |
| Bone marrow | |||
| Yes | 143 (42) | 67 ± 4 | <.0001 |
| No | 201 (58) | 90 ± 2 | |
| Other localizations | |||
| Mediastinal tumor | 26 (8) | ||
| Pleura | 55 (16) | ||
| Pericardium | 11 (3) | ||
| Spleen | 43 (13) | ||
| Liver | 49 (14) | ||
| Tonsils | 16 (5) | ||
| Thyroid | 7 (2) | ||
| Uterus/adnexa | 13 (4) | ||
| Testes/ovaries | 23 (7) | ||
| Kidney | 16 (5) | ||
| Lung | 8 (2) | ||
| Stomach | 31 (9) | ||
| Gut | 85 (25) | ||
| Bone | 28 (8) | ||
| Other | 76 (23) | ||
| Stage | |||
| I-II | 100 (29) | 90 ± 3 | .002 |
| III-IV | 249 (71) | 76 ± 3 | |
| IPI | |||
| low (0-2) | 140 (49) | 90 ± 3 | .0005 |
| high (3-5) | 146 (51) | 75 ± 4 | |
| aaIPI | |||
| low (0-1) | 111 (37) | 93 ± 3 | <.0001 |
| high (2-3) | 192 (63) | 74 ± 3 | |
Median age was 42 years (range 16-85 years).
aaIPI, age-adjusted IPI; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase.